Objective: Extensive drug resistant Gram-negative bacilli, harboring New Delhi metallo-β-lactamase-1 (bla NDM-1 ) having the ability to hydrolyze β-lactams, have become a vital global clinical threat. The present study was, therefore, designed to investigate the prevalence and epidemiology of NDM-1 producers in Quetta, Pakistan. Methods: This study was carried out in Microbiology Laboratory, Bolan Medical Complex Hospital Quetta, Biotechnology laboratory, BUITEMS Quetta and Hi-tech laboratory, CASVAB, University of Balochistan, Quetta, from March to June 2018, during the hot season. Biochemical and molecular approaches were applied for the identification of bacterial isolates. Minimum Inhibitory Concentrations (MICs) were determined using E-test method. Carbapenemase activity was ascertained by Modified Hodge Test (MHT) and the presence of bla NDM-1 gene was recognized by Polymerase Chain Reaction (PCR). Results: We isolated five bla NDM-1 harboring isolates of three different species namely Morganella morganii (n=2) Enterobacter cloacae (n=2) and Citrobacter freundii (n=1), from 300 pus samples. These isolates were found extensive drug resistant (XDR). Strikingly, two isolates of M. morganii were displaying resistance against 23 antibiotics of sulphonamides, aminoglycosides, polypeptide, monobactams, tetracyclines, quinolones, macrolides, cephalosporins, phosphonic acid and β-lactams groups, suggesting Pan Drug Resistance (PDR). Conclusion: This is the first report on emergence of PDR strain of M. morganii producing NDM1 in the province of Balochistan, Pakistan. The presence of bla NDM-1 in different bacterial species and their extensive rather pan drug resistance pattern poses a momentous clinical threat.
INTRODUCTION
Carbapenem group of antibiotics is one of the most effective drugs that has been used as a last remedy for the treatment of infections caused by Multi Drug Resistant (MDR) Gram negative bacilli. 1 To neutralize the drugs, such NDM-1 producing bacteria encode various carbapenemases which are β-lactamases, having the ability to hydrolyze majority of β-lactams including carbapenems. 2 Irrational use of antimicrobials give birth to resistance by increasing selective pressure in the bacterial population. According to the latest reports on antimicrobial resistance βlactamases are suggested to contribute to resistance. 3 M. morganii and E. cloacae which are members of Enterobacteriaceae family play a significant role in causing nosocomial infections like, wounds, skin, soft tissue, urinary tract, respiratory tract, and biliary tract, mostly in immunocompromised patients. NDM-1 was reported from different hospitals in the UK in Morganella morganii, Citrobacter freundii, Enterobacter cloacae, Providencia, Klebsiella pneumonia and Escherichia coli. 4, 5 It was initially discovered in 2008 in a Swedish patient of Indian origin, but now has claimed its presence globally including India and Pakistan. 5, 6 United Kingdom, Canada, France, China, Japan, Oman, Iraq, Bangladesh and United States are one of the few other countries from where bla NDM-1 has been reported. 6 The emergence of carbapenem resistance, mostly associated with Enterobacteriaceae, raised with the ability of rapid clonal distribution due to its presence on mobile elements such as plasmids. 5, 7 There are random reports of the isolation of bla NDM-1 from different parts of Pakistan. 5, 8, 9 However, such studies have never been reported from the province of Balochistan. The purpose of this study was therefore, to unleash the prevalence and epidemiology of NDM-1 producers from clinical samples in Quetta, Pakistan.
METHODS
Three hundred patients of both genders, adults and children from surgical wards, burn wards, and burn intensive care units (ICU's) of three tertiary care hospitals (Bolan Medical Complex Hospital, Sandeman Provincial Hospital and Fatima Jinnah Chest Hospital) in Quetta were selected in this study. Detailed history was taken from each patient regarding, wound, time and duration of pus discharge, previous antibiotic therapy, pre-existing clinical complications and the areas/climate from where they belonged to. Those patients were preferred for the study whose pus was still oozing from their wounds after several antibiotic therapies. Antibiotic therapy of the patients was discontinued for 72 hours before sample collection. and with sterile cotton swabs (prepared in lab) from surgical/burn wounds of the patients were taken aseptically. The surface area of the wound was cleaned with sterilized cotton. Efforts were made to collect fresh pus from inside the wound after applying slight pressure. Samples were labeled and transported to the Microbiology laboratory immediately. All the samples were inoculated within one hour of collection. Phenotypic and genotypic characterization of bacterial isolates: Conventional microbiological procedures were adopted for bacterial isolation from pus samples. Each sample was streaked simultaneously on MacConkey and Blood agar plates (Oxoid, United Kingdom) followed by incubation aerobically at 37°C for 24 hours. 10 Plates were observed for bacterial colonies and the isolated colonies were further triple cloned. Isolates were identified by analytical profile index, API 20E system (bioMerieux, France) according to the manufacturer's instructions (http://www. biomerieux-usa.com/clinical/api). Thermo Scientific Genomic Purification Kit, Lithuania, was used for DNA extraction, according to the manufacturer's instructions. Internal fragment of 1500 bp of 16S rDNA gene was amplified using universal primers, 27F-5'-AGA GTT TGA TCC TGG CTC AG -3' and RD1-5'-AAG GAG GTG ATC CAG CC -3' with Initial denaturation 95°C for 2 min, followed by 35 cycles of 30 sec. at 95°C, 30 sec. at 55°C and 2 min at 72°C. Final extension was set at 72°C for 10 min. The MICs were performed by the E-test method (Oxoid UK and Liofilchem Italy). Interpretation of the results was based on CLSI 13 and Food and Drug Administration (FDA).
14 breakpoints and recommendations.
Identification of carbapenemase producers:
Phenotypic detection of carbapenemase enzyme activity of bacterial isolates was achieved by Modified Hodge Test (MHT), as described by (CLSI). 12 American Type Culture Collection (ATCC) strains of Klebsiella pneumoniae BBA 1706 (negative control), Klebsiella pneumoniae BBA 1705 (positive control) and Escherichia coli 25922, were used in the assay. Amplification of bla NDM-1 producers: Plasmid DNA was extracted for selected phenotypically carbapenems resistant isolates using GeneJET Plasmid Miniprep Kit by Thermo Fisher Scientific Lithuania, according to the manufacturer's instructions. The bla NDM-1 gene was amplified with the following set of primers; bla NDM-1 F-5'-GGG CAG TCG CTT CCA ACG GT-3' and bla NDM-1 R5'-GTA GTG CTC AGT GTC GGC AT -3'. Conditions for PCR were set to; initial denaturation at 95°C for 5 min, followed by 30 Cycles of 95°C for 40 sec, 58°C for 30 sec, 72°C for 30 sec with final extension 72°C for 5 min.
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Sequencing and analysis: Sequencing of the PCR product of 16S rDNA and bla NDM-1 genes of the representative samples was carried out commercially through Macrogen, South Korea. Deduced sequences were aligned using Basic Local Alignment Search Tool (BLAST). NCBI at (https:// blast.ncbi.nlm.nih.gov/Blast.cgi).
RESULTS

Overall abundance of bacterial isolates from pus samples:
Of the 300 pus samples, 102 (34%) showed no bacterial growth whereas, 198 (66%) exhibited bacterial growth on MacConkey and blood agar plates after aerobic incubation at 37°C for 24 hrs. Based on cultural, biochemical and morphological characterization, and using API system, 10 different bacterial types were tentatively identified, which included Staphylococcus aureus (n=56) and Klebsiella pneumoniae (n=39) as predominant, while Acinetobacter baumannii (n=6) and Morganella morganii (n=2) were the least dominant (Fig.1) . Susceptibility testing: All Gram-negative isolates of different spp. subjected to antibiogram were sensitive to a range of antibiotics except, Morganella morganii, (n=2)
The resistance pattern of these isolates indicated that these are XDR and/or PDR (Table-I and Fig.2 ). Phenotypic identification of carbapenemase producers: All five isolates, Morganella morganii, (n=2), Enterobacter cloacae (n=2) and Citrobacter freundii (n=1), were subjected to MHT for phenotypic detection of carbapenemase enzyme activity as described by CLSI. 12 Out of 5 bla NDM-1 producers, four gave positive clover-leaf like indentation whereas, isolate Ec-93 was negative. The sensitivity of the test was 80%. 16S rDNA gene-based identification of bla NDM-1 producers: All five suspected bla NDM-1 producers were successfully amplified for 16S rDNA gene. The amplified products (1500 bp) of the representative isolates were sequenced. The obtained sequences were BLAST to ascertain the molecular based Drug resistance in bacterial isolates 15 Importantly, isolate that gave negative MHT result was also found harboring bla NDM-1 gene. Representative PCR amplified products were sequenced. The retrieved sequences, as a result of BLAST, showed 99% similarity to the previously reported bla NDM-1 genes. https://blast.ncbi.nlm.nih. gov/Blast.cgi
DISCUSSION
New Delhi Metallo-β-lactamase-1 (bla NDM-1 ), which was initially reported in a Swedish patient of Indian origin in 2008, 5 has become an alarming clinical threat and economical burden particularly in developing countries like Pakistan, India and Balkan. 16 Since then it has spread globally with a continuous increase in many countries of Asia, Europe, America, Australia and Africa. 17 In the present study we isolated five extensive and/or pan drug resistant NDM-1 producers belonging to carbapenem resistant Enterobacteriaceae (CRE) of three different spp. from three hundred pus samples. bla NDM-1 gene was detected in Morganella morganii, (n=2), Enterobacter cloacae (n=2) and Citrobacter freundii (n=1). Of all Enterobacteriaceae in our study, NDM-1 was present in 4.27 % as opposed to 2.7% in Kuwait, 1.2% reported in Pakistan, India and the United Kingdom and 1.1% reported in Vietnam. 5, 18 This increase in the prevalence of NDM-1 is alarming in the region.
Multi drug resistance was observed in NDM-1 and NDM-5 variants that exhibited resistance to ciprofloxacin, amikacin and aztreonam, and pan drug resistance in other variants like NDM-4, NDM-7 and NDM-9 that showed resistance to nearly all antimicrobials used in clinical practice excluding tigecycline and colistin. 19 In the present work all our isolates harboring NDM-1 variant were showing resistance to ciprofloxacin, amikacin and aztreonam, and Morganella morganii to tigecycline and colistin as well.
In an epidemiological report the occurrence of carbapenem resistance in the Asian countries from 2002-2012 was 2.4% to meropenem and 1.9% to imipenem, 20 and in a study from Pakistan in 2018 was 56%. 21 The resistance pattern of Morganella morganii, (67%), Enterobacter cloacae (18%) and Citrobacter freundii (11%) to the carbapenems was quite variable in our case.
In Southwest China resistance pattern of Enterobacter cloacae (CRE) was substantial against meropenem, ciprofloxacin, gentamycin, imipenem, tobramycin, levofloxacin and cefepime. Remarkably 65.9% were kept in the category of Mohammad Din et al. Morganella morganii indeed show resistance to polymyxin B and E, when isolated from blood and urine specimens was efficiently treated by combination therapy of fosfomycin in double dose and meropenem. 23 Isolate Mm-4232 showed resistance to β-lactams together with carbapenems, in combination with trimethoprimsulfamethoxazole and aminoglycosides, was kept in the category of extensive drug resistance. Only fosfomycin was left as last choice of treatment. 23 Regarding sensitivity pattern, in 170 non-β-lactam antimicrobials, polymyxin-B was (83%), colistin (83%) and tigecycline (98%). 24 However, isolates of the same microbe (Mm-141 and Mm-234) in our investigations displayed outstanding resistance against twenty-three available antibiotics belonging to cephalosporins, monobactams, quinolones, tetracyclines, β-lactams, aminoglycosides, macrolides, phosphonic acid, penicillins, polypeptides and sulphonamides classes, including the ones mentioned in the above studies.
Citrobacter freundii WCHCF65 isolated from hospital sewage showed resistance to meropenem, ciprofloxacin, imipenem and ceftazidime and was sensitive to tigecycline, colistin and amikacin, 25 whereas isolate Cf-276 of the same sp. in the present study was sensitive to colistin and tigecycline but resistant to amikacin showing extensive resistance pattern and genetic diversity. MICs of imipenem, tigecycline, polymyxin-B, colistin and ceftriaxone exhibited extensive and pan resistance pattern. Viewing sensitivity pattern, these carbapenemase producers may be kept in the category of XDR and/ or PDR.
The presence of NDM-1 in diverse microbial species necessitates precise and early detection particularly in view of the limited treatment options available. Addressing the issue, our investigations clearly suggest PCR assays more sensitive (100% sensitivity). than Modified Hodge test (80% sensitivity) in case of NDM-1 carbapenemase producers.
To the best of our knowledge, this is the maiden report on NDM producers in Balochistan, and pan drug resistant Morganella morganii in Pakistan. The present study not only revealed the presence of three different bacterial species harboring bla NDM-1 in the population of Balochistan, the largest province of Pakistan, but also profiled their extensive and pan drug resistance pattern against a range of antibiotics including carbapenems.
CONCLUSION
Our study which intended to interpret the first detection, prevalence and epidemiology of NDM-1producers in clinical samples from Quetta, Pakistan, indicated five isolates harboring bla NDM-1 , showing resistance to a range of antibiotics including carbapenems. Importantly, two isolates of Morganella morganii displayed resistance against all 23 antibiotics used in the study. The spread of bla NDM-1 , extensive and pan drug resistance, lack of new antimicrobials particularly in carbapenem resistant Enterobacteriaceae (CRE) is an alarming clinical threat.
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